Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. (NYSE: DVA) is a comprehensive kidney care provider whose news flow reflects its clinical, operational and financial activities in the kidney dialysis centers industry. Company press releases and updates highlight its focus on transforming care delivery for patients with kidney disease, its large global network of outpatient dialysis centers and its role in integrated kidney care and value-based care models.
News about DaVita often covers quarterly financial and operating results, where the company reports consolidated revenues, operating income, cash flow and key U.S. dialysis metrics such as treatment volumes, revenue per treatment and patient care costs per treatment. These releases may also discuss share repurchases, debt transactions, credit facility amendments and guidance ranges for adjusted operating income, adjusted diluted net income per share and free cash flow.
Investors and observers can also find updates on clinical research and innovation. DaVita publishes information about studies presented at events like the American Society of Nephrology’s Kidney Week, including research on GLP-1 receptor agonist use in end-stage kidney disease, home dialysis outcomes, transplant access and end-of-life care. Additional news may describe initiatives such as the MODEL and MEMOIRS evaluations of medium cut-off dialyzers and efforts to better understand middle-molecule clearance.
Other DaVita news items include leadership appointments, participation in investor conferences and statements on government programs such as the Kidney Care Choices (KCC) Model. These communications provide insight into the company’s strategy, governance, integrated kidney care footprint and engagement with value-based care initiatives. For ongoing context on DVA, readers can use this news feed to follow developments in DaVita’s kidney care operations, research programs and capital allocation decisions over time.
DaVita Giving Foundation announced an investment in the National Kidney Foundation's PEERS program, which provides social and emotional support for patients, care partners, and living donors through mentor connections. The program currently has over 356 participants as mentors and mentees, with 81% managing chronic illnesses like kidney failure.
The initiative aims to address mental health challenges in chronic disease care, as patients with chronic conditions are more likely to experience depression. The program facilitates telephone-based connections between participants, allowing them to discuss their kidney care journey with others who have similar experiences.
DaVita Clinical Research (DCR) will present five research projects at ASN's Kidney Week 2024 in San Diego. The research focuses on improving racial equity in transplantation and clinical quality measures. Studies examine topics including: the impact of nephrologist visits on hospitalization rates, racial disparities in transplant processes among Hispanic dialysis patients, effects of heavy precipitation on dialysis treatment attendance, early indicators of ESKD transition in AKI-dialysis patients, and blood pressure thresholds in CKD patients. The presentations aim to enhance upstream CKD care management and promote health equity.
DaVita announced performance year one clinical outcomes achieved through value-based care arrangements with nearly 1,300 nephrologists across the U.S. These efforts are part of the Comprehensive Kidney Care Contracting (CKCC) option within the government's voluntary Kidney Care Choices (KCC) model, which began on Jan. 1, 2022.
Key achievements include:
- 16% industry increase in optimal start rates for kidney patients transitioning to dialysis
- Embedding care team members in 68% of nephrology practices
- Overseeing approximately 31,000 patients across multiple care settings
- 2.4x more DaVita patients having a planned start on home treatment
- 67% of patients screened for depression remission
- 13% increase in patient activation
DaVita's tech-enabled platform and increased CKD education efforts have contributed to these improvements. The company expects continued progress in outcomes and cost savings as the CKCC program evolves.
DaVita, a leading kidney care services provider, has appointed Jessica Hergenreter as its new chief people officer (CPO). Hergenreter will lead the People Services team, overseeing initiatives to engage and support DaVita's 70,000+ global employees. The company was recently recognized as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek.
Hergenreter brings 13 years of experience from Vail Resorts, where she held various leadership roles and most recently led talent strategies for 55,000 employees. Her focus areas included talent acquisition, development, and fostering diversity and inclusion. DaVita's CEO, Javier Rodriguez, expressed enthusiasm about Hergenreter's appointment, citing her fresh energy and innovative ideas to drive initiatives for attracting and retaining top talent.
DaVita Kidney Care has opened its dialysis centers in Florida to anyone needing treatment following Hurricane Milton, including patients from other providers. Patients can call DaVita Guest Services at 1-800-400-8331 for help locating centers and scheduling treatment. Approximately 50,000 Floridians with kidney failure currently receive dialysis treatment.
DaVita activated its emergency response plan before the hurricane, proactively dialyzing thousands of patients in over 150 centers. The company has deployed water tankers, fuel tankers, generators, supplies, and medication across Florida to ensure centers can treat patients in impacted areas as soon as possible. DaVita's national emergency management team is supporting affected centers and routing patients to safe locations for care.
DaVita Inc. (NYSE: DVA) has announced its upcoming third quarter 2024 investor conference call, scheduled for Tuesday, October 29, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close on the same day. Investors can access the call via webcast or by dialing in, with the password "Earnings" required.
DaVita, a comprehensive kidney care provider, serves approximately 265,100 patients at 3,124 outpatient dialysis centers globally as of June 30, 2024. The company operates 2,672 centers in the United States and 452 centers across 13 other countries. DaVita focuses on transforming care delivery to improve patients' quality of life, offering services from slowing kidney disease progression to supporting transplantation and providing dialysis at home.
DaVita Kidney Care has activated its emergency response plan in preparation for Hurricane Milton's landfall in Florida. The company is proactively dialyzing thousands of patients ahead of the storm in over 150 centers. DaVita's priorities are safety and continuity of care for approximately 50,000 Floridians who receive dialysis treatment.
Local teammates are providing patients with medical information and evacuation details. DaVita is coordinating with other healthcare providers to ensure continuity of care and will track patient transfers. Patients and families can visit DaVita's newsroom for center closure updates or call DaVita Guest Services for assistance.
The company emphasizes the importance of emergency preparedness for kidney patients, recommending an emergency kit with essential items such as medication, medical supplies, and emergency contact information.
DaVita (NYSE: DVA), a leading kidney care provider, has announced its 2024 nationwide community health tour starting September 24. The DaVita Health Tour offers free health screenings and chronic disease education across the country. This year's tour features an enhanced experience in collaboration with the American Diabetes Association (ADA), focusing on diabetes and chronic kidney disease (CKD) education, especially for underserved populations.
The tour will provide free screenings in California, Florida, Georgia, Pennsylvania, and Texas, regions with higher kidney disease prevalence. Screenings include glucose tests, blood pressure readings, BMI calculations, and optional blood draws for detailed kidney function assessment. This initiative aims to identify potential risk factors for CKD, diabetes, and hypertension early, allowing for timely intervention.
DaVita (NYSE: DVA), a leading kidney care provider, has announced key leadership changes effective September 15, 2024. David Maughan, an 18-year DaVita veteran, will become the new chief operating officer, succeeding Mike Staffieri, who transitions to chief operating officer emeritus after 11 years in the role.
Maughan brings extensive experience, having held various leadership positions at DaVita, including overseeing strategic functions for hospital and home treatment businesses. His leadership has impacted over 65,000 employees and 200,000 patients. Staffieri, with a 25-year tenure at DaVita, will continue working on key strategic initiatives to drive clinical differentiation in kidney care.
As of June 30, 2024, DaVita served approximately 265,100 patients at 3,124 outpatient dialysis centers globally, with 2,672 centers in the United States and 452 in 13 other countries.
DaVita Inc. (NYSE: DVA) has announced the pricing of a $1.0 billion private offering of 6.875% senior notes due 2032. The notes were priced at 100.000% of their face value, yielding a 6.875% coupon. The offering is expected to close on August 13, 2024, subject to customary conditions.
DaVita plans to use the net proceeds to repay a portion of its outstanding Term Loan B-1 facility maturing in 2026 and a portion of its revolving credit facility borrowings, pay related costs, and for general corporate purposes, including potential stock repurchases. The notes were offered only to qualified institutional buyers and certain non-U.S. persons, and have not been registered under the Securities Act.